Difference between revisions of "Camrelizumab (AiRuiKa)"
m |
m |
||
Line 9: | Line 9: | ||
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
+ | *[[Non-small cell lung cancer, squamous]] | ||
==Also known as== | ==Also known as== | ||
Line 21: | Line 22: | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
+ | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] |
Revision as of 11:50, 5 May 2022
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Toxicity management
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
Also known as
- Code names: HR-301210, SHR-1210
- Brand name: AiRuiKa